[Skip to Content]
[Skip to Content Landing]
Views 677
Citations 0
Observation
February 2018

Stevens-Johnson Syndrome During Pregnancy: Case Report of a Newborn Treated With the Culprit Drug

Author Affiliations
  • 1AP-HP, Hôpital Henri-Mondor, Department of Dermatology, Creteil, France
  • 2Referral Center for Toxic Bullous Diseases, Île-de-France, France
  • 3EA EpiDermE 7379, UPEC Université Paris Est-Créteil Val-de-Marne, France
JAMA Dermatol. 2018;154(2):224-225. doi:10.1001/jamadermatol.2017.4607

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare life-threatening cutaneous drug reactions. The pathogenesis is imperfectly understood and includes genetic factors.1 Pregnant women with SJS or TEN are a unique subset, and both conditions can simultaneously affect the mother and fetus.2-4 There are no data on the risk of SJS or TEN in a newborn of a mother who develops the condition during pregnancy if soon after delivery the newborn is given the same drug that triggered the mother’s reaction. We report the case of a pregnant woman with SJS whose newborn was successfully treated with the drugs responsible for his mother’s SJS.

×